Our results support this hypothesis, as repeated IFN therapy via i.m. route (group F) may have resulted in longer bioavailability of chIFN-α in serum over the course of experiment and consequently in better protection from the infection compared to single-dose treatment (group E). This evidence concerns the gene IFNA1 and infection.